CN117597361A - 异二聚体抗体和其抗原结合片段 - Google Patents

异二聚体抗体和其抗原结合片段 Download PDF

Info

Publication number
CN117597361A
CN117597361A CN202280030146.3A CN202280030146A CN117597361A CN 117597361 A CN117597361 A CN 117597361A CN 202280030146 A CN202280030146 A CN 202280030146A CN 117597361 A CN117597361 A CN 117597361A
Authority
CN
China
Prior art keywords
amino acid
acid residue
region
polypeptide complex
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030146.3A
Other languages
English (en)
Chinese (zh)
Inventor
周桢昊
张洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chimagen Biosciences Ltd
Original Assignee
Chimagen Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimagen Biosciences Ltd filed Critical Chimagen Biosciences Ltd
Publication of CN117597361A publication Critical patent/CN117597361A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280030146.3A 2021-04-23 2022-04-22 异二聚体抗体和其抗原结合片段 Pending CN117597361A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/089400 2021-04-23
CN2021089400 2021-04-23
PCT/CN2022/088386 WO2022223016A1 (en) 2021-04-23 2022-04-22 Heterodimeric antibodies and antigen-binding fragment thereof

Publications (1)

Publication Number Publication Date
CN117597361A true CN117597361A (zh) 2024-02-23

Family

ID=83721948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280030146.3A Pending CN117597361A (zh) 2021-04-23 2022-04-22 异二聚体抗体和其抗原结合片段

Country Status (7)

Country Link
US (1) US20240182576A1 (https=)
EP (1) EP4326772A4 (https=)
JP (1) JP2024517671A (https=)
CN (1) CN117597361A (https=)
AU (1) AU2022261269A1 (https=)
CA (1) CA3217487A1 (https=)
WO (1) WO2022223016A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202506741A (zh) * 2023-04-06 2025-02-16 美商麥迪紐有限責任公司 工程化抗體
WO2025103355A1 (zh) * 2023-11-14 2025-05-22 信达生物制药(苏州)有限公司 抗egfr和her3双特异性抗体-药物偶联物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60499B1 (sr) * 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US10118971B2 (en) * 2013-03-13 2018-11-06 Ibentrus, Inc. Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
ES2936810T3 (es) * 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
KR102669686B1 (ko) * 2015-04-28 2024-05-29 자임워크스 비씨 인코포레이티드 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109475627B (zh) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
MX2019005552A (es) * 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
WO2020028269A2 (en) * 2018-07-30 2020-02-06 Invenra Inc. Multispecific treg binding molecules
AU2019412561A1 (en) * 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
CN111484555B (zh) * 2019-01-28 2022-07-08 正大天晴药业集团股份有限公司 新型双特异性cd3/cd20多肽复合物
JP7500619B2 (ja) * 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作

Also Published As

Publication number Publication date
US20240182576A1 (en) 2024-06-06
EP4326772A4 (en) 2025-03-05
WO2022223016A1 (en) 2022-10-27
AU2022261269A1 (en) 2023-11-09
JP2024517671A (ja) 2024-04-23
EP4326772A1 (en) 2024-02-28
CA3217487A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
CN119039441A (zh) 与nkp30结合的抗体分子及其用途
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
JP2020511997A (ja) 腫瘍抗原提示誘導物質構築物及びその使用
CN116888153A (zh) 与γ-δT细胞受体结合的抗体
JP2022525275A (ja) ヘテロ多量体タンパク質及びその使用法
CN121758617A (zh) 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
WO2024131962A1 (zh) 新型抗gprc5d抗体
CA3180507A1 (en) Heterodimeric proteins
US20240182576A1 (en) Heterodimeric antibodies and antigen-binding fragment thereof
CN120917051A (zh) 多特异性抗原结合蛋白及其用途
EP4238986A1 (en) Fc monomer polypeptide and application thereof
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
WO2025162031A1 (zh) 一种靶向TfR1的单域抗体及其应用
JP2025540657A (ja) 抗ｃｄ３抗体
WO2024027120A1 (en) Multi-specific polypeptide complexes
WO2024149381A1 (en) Multi-specific polypeptide complexes
WO2025026282A1 (en) Modified type e multi-specific antibodies
JP7671356B2 (ja) 安定性および発現が改良されたポリペプチド複合体
TWI830124B (zh) 具有改善的穩定性和表現的多肽複合物
EP4640715A1 (en) Multi-specific polypeptide complex targeting gprc5d
WO2025092987A9 (zh) 基于Fc区的异二聚体分子及其用途
IL323119A (en) Isolated bispecific antibodies that bind uniquely to CD3 and a cancer antigen and their use
CN116120461A (zh) 新型抗药抗体以及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination